Moïsi Jennifer C, Makawa Makawa-Sy, Tall Haoua, Agbenoko Kodjo, Njanpop-Lafourcade Berthe-Marie, Tamekloe Stanislas, Amidou Moussa, Mueller Judith E, Gessner Bradford D
Agence de Médecine Préventive, Paris, France.
Ministry of Health, Lomé and Dapaong, Togo.
PLoS One. 2017 Jan 23;12(1):e0170412. doi: 10.1371/journal.pone.0170412. eCollection 2017.
S. pneumoniae is a leading cause of meningitis morbidity and mortality in the African meningitis belt, but little is known of its contribution to the burden of pneumonia in the region. We aimed to estimate the incidence of pneumococcal disease in children and adults in northern Togo, before the introduction of pneumococcal conjugate vaccine (PCV).
From May 1st 2010 to April 30th 2013, we systematically enrolled all hospitalized patients meeting a case definition of suspected meningitis or clinical pneumonia, residing in Tone or Cinkasse districts, northern Togo and providing informed consent. We collected clinical data and tested biological specimens according to standardized procedures, including bacteriology and PCR testing of cerebro-spinal fluid for meningitis patients and blood cultures and whole blood lytA PCR for pneumonia patients. Chest X-rays (CXR) were interpreted using the WHO methodology. We included 404 patients with meningitis (104 <5 years of age) and 1550 with pneumonia (251 <5 years) over the study period. Of these, 78 (19%) had pneumococcal meningitis (13 <5 years), 574 (37%) had radiologically-confirmed pneumonia (83 <5 years) and 73 (5%) had culture-confirmed pneumococcal pneumonia (2 <5 years). PCV13 serotypes caused 79% (54/68) of laboratory-confirmed pneumococcal meningitis and 83% (29/35) of culture-confirmed pneumococcal pneumonia. Serotype 1 predominated in meningitis (n = 33) but not in pneumonia patients (n = 1). The incidence of pneumococcal disease was 7.5 per 100,000 among children <5 years of age and 14.8 in persons 5 years of age and above in the study area. When considering CXR-confirmed and blood PCR-positive pneumonia cases as likely pneumococcal, incidence estimates increased to 43.7 and 66.0 per 100,000 in each of these age groups, respectively. Incidence was at least 3-fold higher when we restricted the analysis to the urban area immediately around the study hospitals.
Our findings highlight the important role of S. pneumoniae as a meningitis and pneumonia-causing pathogen in the African meningitis belt. Pneumococcal disease incidence in our population was substantially lower than expected from global models; we hypothesize that poor access to hospital care led us to substantially underestimate the burden of disease. Surveillance is ongoing and will enable an evaluation of PCV impact, providing novel, high quality data from the region.
肺炎链球菌是非洲脑膜炎带地区脑膜炎发病和死亡的主要原因,但对于其在该地区肺炎负担中的作用却知之甚少。我们旨在估计在引入肺炎球菌结合疫苗(PCV)之前,多哥北部儿童和成人中肺炎球菌疾病的发病率。
2010年5月1日至2013年4月30日,我们系统招募了所有居住在多哥北部托内或辛卡斯地区、符合疑似脑膜炎或临床肺炎病例定义并签署知情同意书的住院患者。我们按照标准化程序收集临床数据并检测生物标本,包括对脑膜炎患者的脑脊液进行细菌学和PCR检测,以及对肺炎患者进行血培养和全血lytA PCR检测。胸部X光片(CXR)采用世界卫生组织的方法进行解读。在研究期间,我们纳入了404例脑膜炎患者(104例年龄<5岁)和1550例肺炎患者(251例年龄<5岁)。其中,78例(19%)患有肺炎球菌性脑膜炎(13例年龄<5岁),574例(37%)患有放射学确诊的肺炎(83例年龄<5岁),73例(5%)患有培养确诊的肺炎球菌性肺炎(2例年龄<5岁)。PCV13血清型导致79%(54/68)的实验室确诊肺炎球菌性脑膜炎和83%(29/35)的培养确诊肺炎球菌性肺炎。血清型1在脑膜炎患者中占主导(n = 33),但在肺炎患者中不占主导(n = 1)。研究区域内,年龄<5岁儿童的肺炎球菌疾病发病率为每10万人7.5例,5岁及以上人群为每10万人14.8例。当将CXR确诊且血PCR阳性的肺炎病例视为可能的肺炎球菌病例时,这两个年龄组的发病率估计分别增至每10万人43.7例和66.0例。当我们将分析限制在研究医院周边的市区时,发病率至少高出3倍。
我们的研究结果凸显了肺炎链球菌作为非洲脑膜炎带地区引起脑膜炎和肺炎病原体的重要作用。我们人群中的肺炎球菌疾病发病率显著低于全球模型预期;我们推测,获得医院治疗的机会有限导致我们大幅低估了疾病负担。监测工作正在进行,这将有助于评估PCV的影响,并提供该地区全新的高质量数据。